Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Rapid and flexible batch production of medicines for early clinical trials

Reference number
Coordinator Extem Pharma AB
Funding from Vinnova SEK 500 000
Project duration November 2025 - July 2026
Status Completed
Venture Innovative Startups
Call Innovative Startups 2025

Important results from the project

Extem Pharma provides services in formulation development and manufacturing of pharmaceutical products for clinical and preclinical studies in both human and veterinary medicine. The objective of establishing the company as a well-known and recognized player has been validated by ongoing discussions with several prospective clients about assignments and quotations. It also became evident that the demand for new, flexible technologies has significant potential across a range of application areas.

Expected long term effects

Developing new business areas enables the company to broaden its customer base and reach additional market segments. This creates opportunities for growth and business expansion. A more diversified customer portfolio reduces dependence on individual customers and sectors, increasing stability and reducing sensitivity to economic fluctuations.

Approach and implementation

The project was carried out through three parallel work packages. The Project Manager coordinated activities and led a team of internal resources and external consultants. To strengthen the company’s market presence, promotional materials, including roll-ups, a logo, an image library, and a communication strategy, were developed. A market analysis based on interviews with customers and partners was conducted, and the company’s value proposition was successfully validated.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 28 August 2026

Reference number 2025-02591